The United States Food and Drug Administration (USFDA) inspected Everest Organics’ Manufacturing Facility at Aroor Village and for the same the company has received the final approval. The USFDA has inspected the same from February 27, 2017 to March 3, 2017.
Everest Organics is engaged in the business of bulk drugs and active pharmaceutical ingredients (APIs). It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen and Benzimadizole.